E-mail this article

To:

Invalid E-mail address

Add a personal message:(80 character limit)Your E-mail:

Invalid E-mail address

Sending your article

Your article has been sent.

Selecta Biosciences, a Watertown company announced last week that it had begun the first clinical trial of SEL-068, a nicotine vaccine. In the same way a flu vaccine revs up your body’s immune system to round up flu viruses, Selecta’s vaccine would train the immune system to capture nicotine molecules in the bloodstream, barring them from entering your brain. Smoking a cigarette would have none of the calming, appetite-reducing, or focus-sharpening effects that smokers seek.

For more from BostonGlobe.com, sign up or log in below

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com